Back to main

4 US IPOs planned for the week of Jul 30

Posted
7/30/2012 8:00:00 AM
By: Renaissance Capital
Referenced Stocks:ELOQ;GMED;LGZ;NGVC;STML

The following IPOs are expected to price this week :

Eloqua ( ELOQ ), which provides on-demand software to automate marketing and sales initiatives, plans to raise $84 million by offering 8.0 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, Eloqua would command a market value of $401 million. Eloqua, which was founded in 1999, booked $85 million in sales over the last 12 months. The Vienna, VA-based company plans to list on the NASDAQ under the symbol ELOQ. J.P. Morgan and Deutsche Bank Securities are the joint bookrunners on the deal.

Globus Medical ( GMED ), which sells spine implants to hospitals for use in surgical procedures, plans to raise $200 million by offering 11.8 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Globus Medical would command a market value of $1.6 billion. Globus Medical, which was founded in 2003, booked $348 million in sales over the last 12 months. The Audubon, PA-based company plans to list on the NYSE under the symbol GMED. BofA Merrill Lynch, Goldman Sachs, Piper Jaffray and Leerink Swann are the joint bookrunners on the deal.

LegalZoom.com ( LGZ ), a provider of online legal services to consumers and small businesses in the US, plans to raise $88 million by offering 8.0 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, LegalZoom.com would command a market value of $483 million. LegalZoom.com, which was founded in 1999, booked $165 million in sales over the last 12 months. The Glendale, CA-based company plans to list on the NYSE under the symbol LGZ. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal.

Stemline Therapeutics ( STML ), a biotech developing treatments that target cancer stem cells and tumor bulk, plans to raise $42 million by offering 3.5 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Stemline Therapeutics would command a market value of $128 million. Stemline Therapeutics was founded in 2003. The New York, NY-based company plans to list on the NASDAQ under the symbol STML. RBC Capital Markets and Oppenheimer & Co. are the joint bookrunners on the deal.

Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.

Last week, there were 7 IPO pricings . Natural Grocers by Vitamin Cottage ( NGVC ), a western retailer of natural and organic groceries and dietary supplements, was the week's winner, ending up 33% from its IPO price.